Constellium (CSTM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Voting matters and shareholder proposals
Ratification and appointment of Ms. Ingrid Joerg as director for a three-year term recommended for approval.
Re-appointment of Mr. John Ormerod as director for a three-year term recommended for approval.
Advisory vote to approve 2025 executive compensation and to hold annual say-on-pay votes recommended for approval.
Approval of statutory and consolidated financial statements for fiscal year ended December 31, 2025 recommended.
Authorization for share repurchase and capital reduction through share cancellation recommended for approval.
Board of directors and corporate governance
Discharge of directors, CEO, and statutory auditors for duties performed in fiscal year 2025 recommended.
Approval of aggregate maximum amount of directors' annual fixed fees recommended.
Executive compensation and say-on-pay
Advisory approval of 2025 compensation for named executive officers recommended.
Annual advisory vote on executive compensation preferred over biennial or triennial options.
Latest events from Constellium
- Revenue up 5% and net income up 73% in Q1 2025, with guidance reaffirmed.CSTM
Q1 20258 Jul 2026 - Q2 2024: Net income rose, cash flow strong, Swiss flooding paused guidance, 2025 target reaffirmed.CSTM
Q2 20248 Jul 2026 - Record Adjusted EBITDA and net income, with raised 2026 outlook and strong liquidity.CSTM
Q1 202629 Apr 2026 - Shareholders will vote on director appointments, executive pay, financials, and share repurchases.CSTM
Proxy filing10 Apr 2026 - Shareholders to vote on director appointments, executive pay, and share repurchase plans after a strong 2025.CSTM
Proxy filing30 Mar 2026 - Record 2025 results, strong cash flow, reduced leverage, and Vision 2028 launched.CSTM
Q4 202518 Feb 2026 - Q3 2024 results were hit by lower volumes, flood losses, and weak demand across key markets.CSTM
Q3 202419 Jan 2026 - 2024 saw lower results from disruptions, but 2025–2028 targets reflect recovery and growth.CSTM
Q4 20246 Jan 2026 - 2025 guidance raised as revenue grows but net income declines on margin pressure.CSTM
Q2 202516 Nov 2025